Endoscopy Room, Heping Hospital Affiliated to Changzhi Medical College, Shanxi, Changzhi, 046000, People's Republic of China.
Teaching Reform Class of 2016, First Clinical College, Changzhi Medical College, Shanxi, Changzhi, 046000, People's Republic of China.
Biosci Rep. 2020 Aug 28;40(8). doi: 10.1042/BSR20201927.
The presence or absence of glutathione S-transferase M1 gene (GSTM1) and glutathione S-transferase T1 gene (GSTT1) polymorphisms, and their combined effects have been suggested as a risk factor for colorectal cancer (CRC). However, the results are inconsistent.
An updated meta-analysis was performed to solve the controversy.
Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines were used.
Overall, the GSTM1 null genotype was associated with an increased CRC risk in Caucasians (odds ratio (OR) = 1.14, 95% confidence interval (CI): 1.05-1.23), Asians (OR = 1.19, 95% CI: 1.08-1.32), high-quality studies (OR = 1.12, 95% CI: 1.06-1.18). Moreover, the GSTM1 null genotype was also associated with an increased colon cancer risk (OR = 1.32, 95% CI: 1.16-1.51). The GSTT1 null genotype was also associated with an increased CRC risk in Asians (OR = 1.08, 95% CI: 1.02-1.15) and Caucasians (OR = 1.24, 95% CI: 1.09-1.41). Moreover, The GSTT1 null genotype was associated with an increased rectal cancer risk (OR = 1.13, 95% CI: 1.01-1.27, I2 = 8.3%) in subgroup analysis by tumor location. Last, the GSTM1 null/GSTT1 null genotype was associated with an increased CRC risk in Asians.
This meta-analysis indicates that the GSTM1 and GSTT1 null genotypes are associated with increased CRC risk in Asians and Caucasians, and the GSTM1 null/GSTT1 null genotype was associated with increased CRC risk in Asians.
谷胱甘肽 S-转移酶 M1 基因(GSTM1)和谷胱甘肽 S-转移酶 T1 基因(GSTT1)缺失多态性的存在与否及其联合作用被认为是结直肠癌(CRC)的危险因素。然而,结果并不一致。
进行更新的荟萃分析以解决争议。
使用观察性研究荟萃分析中的 MOOSE 指南。
总体而言,GSTM1 无效基因型与白种人(比值比(OR)=1.14,95%置信区间(CI):1.05-1.23)、亚洲人(OR=1.19,95%CI:1.08-1.32)、高质量研究(OR=1.12,95%CI:1.06-1.18)的 CRC 风险增加相关。此外,GSTM1 无效基因型也与结肠癌风险增加相关(OR=1.32,95%CI:1.16-1.51)。GSTT1 无效基因型也与亚洲人(OR=1.08,95%CI:1.02-1.15)和白种人(OR=1.24,95%CI:1.09-1.41)的 CRC 风险增加相关。此外,在按肿瘤位置进行的亚组分析中,GSTT1 无效基因型与直肠癌风险增加相关(OR=1.13,95%CI:1.01-1.27,I2=8.3%)。最后,GSTM1 无效/GSTT1 无效基因型与亚洲人的 CRC 风险增加相关。
本荟萃分析表明,GSTM1 和 GSTT1 无效基因型与亚洲人和白种人 CRC 风险增加相关,GSTM1 无效/GSTT1 无效基因型与亚洲人 CRC 风险增加相关。